睿知中国医院研究地图
候选清单

正在招募食管鳞状细胞癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC

ClinicalTrials.gov 上登记的一项食管鳞状细胞癌开放试验,由西安交通大学第一附属医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方西安交通大学第一附属医院First Affiliated Hospital of Xi'an Jiaotong University西安医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07796113,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed esophageal squamous cell carcinoma (ESCC).

    入选标准第 2 条

  3. Thoracic esophageal cancer evaluated by CT, MRI, or EUS, with clinical stage T1b-T2N+ or T3-T4a, any N (according to the AJCC 8th edition).

    入选标准第 3 条

  4. Expected to achieve R0 resection after neoadjuvant therapy.

    入选标准第 4 条

    Women of childbearing potential must have a negative serum pregnancy test within 72 hours prior to first dosing and must agree to use effective contraception (such as intrauterine device, oral contraceptives, or condoms) during the study and for at least 3 months after the last dose.Male participants with partners of childbearing potential must be surgically sterile or agree to use effective contraception during the study and for 3 months after the last dose.

    入选标准第 19 条

  5. **ECOG performance status of 0-1.

    入选标准第 6 条

  6. Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L

    入选标准第 11 条

    Platelet count ≥ 100 × 10⁹/L

    入选标准第 12 条

    Hemoglobin ≥ 90 g/L b) Serum biochemistry:

    入选标准第 13 条

    Total bilirubin ≤ 1.5 × ULN

    入选标准第 14 条

    ALT ≤ 2.5 × ULN, AST ≤ 2.5 × ULN

    入选标准第 15 条

    Serum creatinine ≤ 1.5 × ULN, or creatinine clearance ≥ 50 mL/min c) Coagulation:

    入选标准第 16 条

    INR ≤ 1.5 × ULN

    入选标准第 17 条

    APTT ≤ 1.5 × ULN

    入选标准第 18 条

  7. History of immunodeficiency, including HIV positivity, other acquired or congenital immunodeficiency disorders, organ transplantation, or allogeneic bone marrow transplantation.

    排除标准第 12 条

    Active hepatitis B (HBV DNA ≥ 2000 IU/mL or ≥ 10⁴ copies/mL) or active hepatitis C infection (HCV antibody positive and HCV RNA above the lower limit of detection).

    排除标准第 17 条

    History of another malignancy within 5 years prior to the first dose, except for malignancies with negligible risk of metastasis or death (e.g., adequately treated basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix).

    排除标准第 18 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:影像与可测量病灶;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07796113,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Signed written informed consent and voluntarily agrees to participate in the study.
  2. Histologically or cytologically confirmed esophageal squamous cell carcinoma (ESCC).
  3. Thoracic esophageal cancer evaluated by CT, MRI, or EUS, with clinical stage T1b-T2N+ or T3-T4a, any N (according to the AJCC 8th edition).
  4. Expected to achieve R0 resection after neoadjuvant therapy.
  5. Age between 18 and 75 years, male or female.
  6. **ECOG performance status of 0-1.
  7. No prior anti-tumor therapy for esophageal cancer, including radiotherapy, chemotherapy, or surgery.
  8. Planned to undergo surgical resection after completion of neoadjuvant therapy.
  9. No contraindications to surgery.
  10. Adequate organ function, defined as follows:
  11. Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L
  12. Platelet count ≥ 100 × 10⁹/L
  13. Hemoglobin ≥ 90 g/L b) Serum biochemistry:
  14. Total bilirubin ≤ 1.5 × ULN
  15. ALT ≤ 2.5 × ULN, AST ≤ 2.5 × ULN
  16. Serum creatinine ≤ 1.5 × ULN, or creatinine clearance ≥ 50 mL/min c) Coagulation:
  17. INR ≤ 1.5 × ULN
  18. APTT ≤ 1.5 × ULN
  19. Women of childbearing potential must have a negative serum pregnancy test within 72 hours prior to first dosing and must agree to use effective contraception (such as intrauterine device, oral contraceptives, or condoms) during the study and for at least 3 months after the last dose.Male participants with partners of childbearing potential must be surgically sterile or agree to use effective contraception during the study and for 3 months after the last dose.
  20. Good compliance and willingness to adhere to study visits and follow-up requirements.

排除标准:Exclusion Criteria:

  1. Tumor invasion into adjacent vital structures of the esophageal lesion (e.g., major arteries or trachea).
  2. Presence of supraclavicular lymph node metastasis.
  3. Presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
  4. Poor nutritional status with BMI < 18.5 kg/m²; patients may be reconsidered for inclusion after nutritional support and investigator assessment.
  5. Known hypersensitivity to monoclonal antibodies, adebrelimab, paclitaxel, cisplatin, or other platinum-containing agents.
  6. Prior or current receipt of any of the following treatments:
  7. Any prior radiotherapy, chemotherapy, or other anti-tumor therapy for esophageal cancer;
  8. Use of immunosuppressive drugs or systemic corticosteroids for immunosuppressive purposes (prednisone >10 mg/day or equivalent) within 2 weeks before the first dose of study drug. Inhaled or topical corticosteroids, or physiologic replacement doses (>10 mg/day prednisone or equivalent) are permitted in the absence of active autoimmune disease;
  9. Receipt of a live attenuated vaccine within 4 weeks before the first dose of study drug;
  10. Major surgery or severe trauma within 4 weeks prior to the first dose of study drug.
  11. Active autoimmune disease or history of autoimmune disease, including but not limited to interstitial pneumonitis, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, or hypothyroidism (patients with thyroid disorders controlled on hormone replacement may be eligible). Patients with psoriasis or childhood asthma/allergies that have resolved without intervention may be eligible, but those requiring bronchodilators are excluded.
  12. History of immunodeficiency, including HIV positivity, other acquired or congenital immunodeficiency disorders, organ transplantation, or allogeneic bone marrow transplantation.
  13. Uncontrolled or clinically significant cardiac conditions, including but not limited to:
  14. Severe infection (CTCAE grade >2) within 4 weeks prior to first dosing, such as pneumonia requiring hospitalization, bacteremia, or other severe infections.
  15. Active tuberculosis (TB) infection confirmed by history or CT findings, history of active TB within 1 year before enrollment, or history of TB more than 1 year prior without adequate treatment.
  16. Tumor encasement of major blood vessels or presence of significant necrosis or cavitation on imaging that, in the investigator's judgment, would increase the risk of bleeding.
  17. Active hepatitis B (HBV DNA ≥ 2000 IU/mL or ≥ 10⁴ copies/mL) or active hepatitis C infection (HCV antibody positive and HCV RNA above the lower limit of detection).
  18. History of another malignancy within 5 years prior to the first dose, except for malignancies with negligible risk of metastasis or death (e.g., adequately treated basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix).
  19. Pregnant or breastfeeding women. 16. Any other condition that, in the investigator's judgment, may interfere with study participation or result in early withdrawal, including severe concomitant diseases (including psychiatric disorders) requiring treatment, alcohol or drug abuse, or social/familial factors that may affect compliance or safety.

引自 ClinicalTrials.gov, NCT07796113, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07796113,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07796113